Positive data from Stage 1 of the Phase IIa clinical trial (QB46C-H07) evaluating QBiotics' small molecule, tigilanol tiglate ...

Provided by PR Newswire Jun 25, 2025, 3:05:00 AM QBIOTICS REPORTS 80% OBJECTIVE RESPONSE RATE IN INJECTED TUMOURS IN STAGE 1 OF PHASE IIA CLINICAL TRIAL OF TIGILANOL TIGLATE FOR SOFT TISSUE SARCOMA ...

Explore how digital biomarkers are transforming clinical trials with real-time data, continuous monitoring and AI-driven patient insights.

An Objective Response Rate (ORR) of 80% was achieved, based on the Best Observed Response (BOR) at any time during the study, indicating 8 out of 10 evaluable patients saw either complete ablation ...

The success of NC Classic also holds a sobering message. If you want to become an Olympic powerhouse, you need dozens of ...

Head-to-head study comparing BioREtain®- processed Amnion Chorion (BR-AC) allograft to standard of care initiated in Q4 2024 ...

Only last month, the Massachusetts-based company was outlining plans to lay off half of its employees in order to focus its ...

The seventh Trial of Aql in Dune: Awakening brings you back to Hagga Rift, only this time, you’ll have to go down to the ...

Media figures' opposition to American patriotism spans decades, with major networks showing how the media view such displays ...

The police will not hand files to prosecutors until after the final report from the public inquiry into the scandal is ...

A research team was looking to make a new anti-inflammatory medication when they found some incredible side effects ...